Interleukin-1 Beta
Interleukin-1 Beta (IL-1β) is a pro-inflammatory cytokine that plays a key role in the regulation of immune and inflammatory responses.
IL-1β is a biomarker for inflammation and is used to diagnose inflammatory conditions.
Key facts at a glance
- Units
- pg/mL
- Clinical utility
- diagnostic
- Result kind
- quantitative
- FDA-cleared
- R&D Systems IL-1beta ELISA, Meso Scale Discovery IL-1beta
Interleukin-1 Beta (IL-1β) is a cytokine that is produced by activated macrophages and is involved in the acute phase response to inflammation. It stimulates the production of other pro-inflammatory cytokines and mediators, contributing to the overall inflammatory response.
Elevated levels of IL-1β are associated with a variety of inflammatory and autoimmune conditions, including rheumatoid arthritis, gout, and sepsis. Measuring IL-1β levels can help in the diagnosis and monitoring of these conditions.
The normal reference range for IL-1β is typically between 0–5 pg/mL. Levels above this range may indicate an inflammatory response or an underlying condition that requires further investigation.
Frequently asked questions
What conditions can cause elevated IL-1β levels?
How is the IL-1β test performed?
Sources
- 1Interleukin-1 BetaSource
- 2
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy